Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
暂无分享,去创建一个
J. Rojas | S. Thorne | W. Hou | P. Sampath
[1] S. Thorne. Immunotherapeutic Potential of Oncolytic Vaccinia Virus , 2014, Front. Oncol..
[2] J. Wolchok,et al. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy , 2014, Science Translational Medicine.
[3] T. Hermiston,et al. Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy , 2014, Front. Immunol..
[4] N. Senzer,et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Bartlett,et al. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[6] M. Bloomston,et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.
[7] D. Pardoll. Immunology beats cancer: a blueprint for successful translation , 2012, Nature Immunology.
[8] R. Vile,et al. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. , 2012, Cancer research.
[9] C. Drake,et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.
[10] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[11] J. Turchi,et al. Abstract 4753: Targeting nucleotide excision repair: Chemical synthetic lethality and biology-based combination therapy , 2012 .
[12] G. Cheng,et al. Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[14] A. Hemminki,et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 , 2011, Gene Therapy.
[15] J. Wolchok,et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps , 2011, Nature Reviews Cancer.
[16] Z. Guo,et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[17] C. Contag,et al. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] S. Kim-Schulze,et al. Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.
[19] S. Chatterjee,et al. Combination of CTL‐associated Antigen‐4 Blockade and Depletion of CD25+ Regulatory T Cells Enhance Tumour Immunity of Dendritic Cell‐based Vaccine in a Mouse Model of Colon Cancer , 2010, Scandinavian journal of immunology.
[20] F. Errington,et al. Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication , 2009, Clinical Cancer Research.
[21] C. Contag,et al. Chemical control of protein stability and function in living mice , 2008, Nature Medicine.
[22] C. Contag,et al. Enhancing poxvirus oncolytic effects through increased spread and immune evasion. , 2008, Cancer research.
[23] D. Kirn,et al. Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus , 2007, PLoS medicine.
[24] D. Kirn,et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. , 2007, The Journal of clinical investigation.
[25] F. Marincola,et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. , 2007, Cancer research.
[26] Drew M. Pardoll,et al. Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.
[27] Jiwon Kim,et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] S. Quezada,et al. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. , 2006, The Journal of clinical investigation.
[29] Andrew Pekosz,et al. Bioluminescence imaging of vaccinia virus: effects of interferon on viral replication and spread. , 2005, Virology.
[30] S. Libutti,et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. , 2001, Cancer research.
[31] J. Allison,et al. Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.
[32] B. Moss,et al. Compact, synthetic, vaccinia virus early/late promoter for protein expression. , 1997, BioTechniques.
[33] J. Allison,et al. Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.
[34] R. Buller,et al. Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling (*) , 1995, The Journal of Biological Chemistry.
[35] S. Thorne,et al. Regulating cytokine function enhances safety and activity of genetic cancer therapies. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.